Related Experiment Videos
The pharmacokinetics and safety of ceftazidime in the neonate
Insights
Ceftazidime (25 mg/kg twice daily) demonstrates safe and effective pharmacokinetic profiles in premature neonates. This antibiotic maintains adequate serum levels, proving well-tolerated for treating infections in this vulnerable population.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Premature neonates often require antibiotic therapy for clinical infections.
- Gentamicin plus penicillin is a common treatment regimen for neonatal infections.
- Understanding ceftazidime's behavior in neonates is crucial for optimizing treatment.
Purpose of the Study:
- To determine the pharmacokinetics and safety of ceftazidime in young, premature neonates.
- To compare intravenous (IV) and intramuscular (IM) administration routes.
- To assess the impact of ceftazidime on biochemical, hematological, and gastrointestinal parameters.
Main Methods:
- Pharmacokinetic analysis of ceftazidime in 41 neonates using High-Performance Liquid Chromatography (HPLC).
- Blood samples collected pre-treatment, during, and post-treatment.
- Biochemical and hematological factors analyzed; fecal specimens tested for Clostridium difficile.
Main Results:
- Higher peak concentrations observed with IV (77 ± 8 mg/l) versus IM (56 ± 7 mg/l) ceftazidime.
- Satisfactory serum levels achieved with both routes throughout the dosage interval.
- Postnatal age significantly influenced total body clearance and serum half-life (P < 0.001).
- No significant adverse effects on biochemical or hematological status; no increased Cl. difficile incidence.
Conclusions:
- Ceftazidime (25 mg/kg twice daily) is safe and well-tolerated in neonates.
- This dosage achieves adequate serum levels in neonates during the first two weeks of life.
- Ceftazidime offers a viable therapeutic option for neonatal infections.
Abstract:
The pharmacokinetics and safety of ceftazidime (25 mg/kg twice daily intravenously or intramuscularly) were determined in 41 young, premature neonates who were clinically infected and would otherwise have received gentamicin plus penicillin. Ceftazidime was assayed in 46 series of blood samples by HPLC. Blood was collected before, during and after treatment for analysis of biochemical and haematological factors. Faecal specimens were examined for the presence of Clostridium difficile and its toxin. Although the peak concentration following iv administration was higher (77 +/- 8 mg/l) than that following im injection (56 +/- 7 mg/l), satisfactory serum levels were maintained throughout the dosage interval using either route. Mean pharmacokinetic profiles following both routes are reported. Postnatal age was the most important factor governing total body clearance (P = 0.0001) and serum half life (P = 0.001). The biochemical and haematological status of the majority of babies remained unaffected by therapy and there was no increase in the incidence of Cl. difficile isolation from stools. Ceftazidime is a safe and well tolerated drug for use in the treatment of neonates. 25 mg/kg administered twice daily results in adequate serum levels in babies during the first two weeks of life.